Thus, our in vitro results revealed that the chemotherapeutic agent doxorubicin can induce TGFβ signaling, promote EMT and generate cells with drug resistant stem cell phenotypes in murine breast cancer 4T1 cells, which could be reversed by the treatment with a TGFβ antagonist TβRI-KI. The gene discussed is TGFBR1; the disease is breast carcinoma.